JANUX THERAPEUTICS INC (JANX)
US47103J1051 - Common Stock
Taking everything into account, JANX scores 4 out of 10 in our fundamental rating. JANX was compared to 578 industry peers in the Biotechnology industry. While JANX has a great health rating, there are worries on its profitability. JANX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year JANX has reported negative net income.
In the past year JANX has reported a negative cash flow from operations.
In the past 5 years JANX always reported negative net income.
JANX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
JANX has a Return On Assets of -8.07%. This is amongst the best in the industry. JANX outperforms 89.95% of its industry peers.
The Return On Equity of JANX (-8.48%) is better than 91.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.07% | ||
| ROE | -8.48% | ||
| ROIC | N/A |
ROA(3y)-13.75%
ROA(5y)-130.91%
ROE(3y)-15.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
JANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, JANX has more shares outstanding
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 39.75 indicates that JANX is not in any danger for bankruptcy at the moment.
The Altman-Z score of JANX (39.75) is better than 96.36% of its industry peers.
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 39.75 |
ROIC/WACCN/A
WACC8.84%
2.3 Liquidity
JANX has a Current Ratio of 62.09. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
JANX's Current ratio of 62.09 is amongst the best of the industry. JANX outperforms 99.65% of its industry peers.
A Quick Ratio of 62.09 indicates that JANX has no problem at all paying its short term obligations.
The Quick ratio of JANX (62.09) is better than 99.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 62.09 | ||
| Quick Ratio | 62.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 24.69% over the past year.
Looking at the last year, JANX shows a very negative growth in Revenue. The Revenue has decreased by -19.68% in the last year.
EPS 1Y (TTM)24.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)-19.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.87%
3.2 Future
Based on estimates for the next years, JANX will show a very negative growth in Earnings Per Share. The EPS will decrease by -14.21% on average per year.
The Revenue is expected to grow by 78.66% on average over the next years. This is a very strong growth
EPS Next Y0.06%
EPS Next 2Y-12.6%
EPS Next 3Y-13.26%
EPS Next 5Y-14.21%
Revenue Next Year-41.49%
Revenue Next 2Y-34.42%
Revenue Next 3Y22.96%
Revenue Next 5Y78.66%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JANX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as JANX's earnings are expected to decrease with -13.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.6%
EPS Next 3Y-13.26%
5. Dividend
5.1 Amount
JANX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JANUX THERAPEUTICS INC
NASDAQ:JANX (6/14/2024, 7:17:23 PM)
After market: 42 0 (0%)42
-0.37 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.18B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.07% | ||
| ROE | -8.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 62.09 | ||
| Quick Ratio | 62.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)24.69%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y0.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.68%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y